Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100723 · ClinicalTrials.gov registry record · Phase 4
Trial to Optimize Mineral Outcomes in Dialysis Patients
A Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT01100723: Completed Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, sponsored by University of Colorado, Denver.
NCT01100723 is a Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism that has completed, run by University of Colorado, Denver. The registered enrollment target is 92 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01100723, a Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is designed to determine if the use of a computer algorithm designed to optimize mineral outcomes in dialysis patients increases the number of patients achieving the desired target endpoints for calcium, phosphorus and parathyroid hormone.
Primary Outcome
Compare the percent of patients achieving an intact Parathyroid hormone (PTH) target of ≤ 300 pg/ml before and after the application of a computerized dosing protocol for management of chronic kidney disease-mineral and bone disorder (CKD-MBD). If multiple values were obtained within a specified evaluation time frame the values were averaged and the average value was then evaluated as to whether it was within or outside the target range.
Conditions Studied
Interventions
- OTHER Cinacalcet, active vitamin D analogue
Study Locations (1)
Virginia
- Lynchburg Nephrology Associates, P.L.L.C. - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
What the finished NCT01100723 record still lists
NCT01100723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Cinacalcet, active vitamin D analogue is the first listed.
NCT01100723 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT01100723 about?
NCT01100723 is a clinical study titled "Trial to Optimize Mineral Outcomes in Dialysis Patients". This trial is designed to determine if the use of a computer algorithm designed to optimize mineral outcomes in dialysis patients increases the number of patients achieving the desired target endpoints for calcium, phosphorus and parathyroid hormone.
What is the current status of trial NCT01100723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2010-03. Estimated completion is 2011-08.
What conditions does trial NCT01100723 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT01100723?
The interventions under investigation include: Cinacalcet, active vitamin D analogue (OTHER).
Who is sponsoring clinical trial NCT01100723?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01100723 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01100723's enrollment target sits among peer trials
92 60th of 101 higher than 42 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
RECRUITING · Phase 4
-
Empagliflozin Treatment in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)
COMPLETED · Phase 4
-
Dialysis Clinical Outcomes Revisited (DCOR) Trial
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia